(Q73519509)

English

Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy

scientific article published on 01 January 2001

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 November 2019

title

Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy (English)

1 reference

stated in

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 November 2019

author name string

Chang E

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 November 2019

Rosenberg SA

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 November 2019

publication date

1 January 2001

1 reference

stated in

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 November 2019

published in

Journal of Immunotherapy

1 reference

stated in

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 November 2019

volume

24

1 reference

stated in

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 November 2019

issue

1

1 reference

stated in

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 November 2019

page(s)

88-90

1 reference

stated in

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

retrieved

4 November 2019

Identifiers

DOI

10.1097/00002371-200101000-00010

1 reference

stated in

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

Europe PubMed Central

PubMed ID

11211152

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211152%20AND%20SRC:MED&resulttype=core&format=json

(Q73519509)

Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)